●药闻快报▲关注药财社聚焦医药界▲1石药康宁杰瑞ADC获突破性认定针对结直肠癌10月20日石药集团宣布,其与康宁杰瑞合作开发的HER2双特异性ADC药物JSKN003又一次次获得CDE授予的突破性疗法认定。适应症为单药用于治疗既往经奥沙利铂、氟尿嘧啶和伊立替康治疗失败的HER2阳性晚期结直肠癌(CRC)。JSKN003是一种靶向HER2双表位ADC,通过糖基定点偶联将TOPO1抑制剂连接至抗体...
Source Link●药闻快报▲关注药财社聚焦医药界▲1石药康宁杰瑞ADC获突破性认定针对结直肠癌10月20日石药集团宣布,其与康宁杰瑞合作开发的HER2双特异性ADC药物JSKN003又一次次获得CDE授予的突破性疗法认定。适应症为单药用于治疗既往经奥沙利铂、氟尿嘧啶和伊立替康治疗失败的HER2阳性晚期结直肠癌(CRC)。JSKN003是一种靶向HER2双表位ADC,通过糖基定点偶联将TOPO1抑制剂连接至抗体...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.